IL1B and oral mucositis: Interestingly, amifostine prevented the immunoexpression of key inflammatory markers, such as TNF-α, IL-1β, and iNOS, confirming the anti-inflammatory effect of that drug and suggesting the potential applicability to manage oral mucositis.